A Detailed Analysis of the Dysmenorrhea Treatment Market Based on Increasing Awareness, and Advancements in Therapeutic Options
Industry: Healthcare
Published Date: February-2024
Format: PPT*, PDF, EXCEL
Delivery Timelines: Contact Sales
Number of Pages: 246
Report ID: PMRREP34024
1. Executive Summary
1.1. Global Dysmenorrhea Treatment Market Snapshot, 2023 and 2030
1.2. Market Opportunity Assessment, 2023 - 2030, US$ Mn
1.3. Key Market Trends
1.4. Future Market Projections
1.5. Premium Market Insights
1.6. Industry Developments and Key Market Events
1.7. PMR Analysis and Recommendations
2. Market Overview
2.1. Market Scope and Definition
2.2. Market Dynamics
2.2.1. Drivers
2.2.2. Restraints
2.2.3. Opportunity
2.2.4. Challenges
2.2.5. Key Trends
2.3. Diseases Lifecycle Analysis
2.4. Dysmenorrhea Treatment Market: Value Chain
2.4.1. List of Raw Material Supplier
2.4.2. List of Manufacturers
2.4.3. List of Distributors
2.4.4. List of Applications
2.4.5. Profitability Analysis
2.5. Porter Five Force’s Analysis
2.6. Geopolitical Tensions: Market Impact
2.7. Macro-Economic Factors
2.7.1. Global Sectorial Outlook
2.7.2. Global GDP Growth Outlook
2.7.3. Global Parent Market Overview
2.8. Forecast Factors - Relevance and Impact
2.9. Regulatory and Technology Landscape
3. Global Dysmenorrhea Treatment Market Outlook: Historical (2018 - 2022) and Forecast (2023 - 2030)
3.1. Key Highlights
3.1.1. Market Volume (Units) Projections
3.1.2. Market Size and Y-o-Y Growth
3.1.3. Absolute $ Opportunity
3.2. Market Size (US$ Mn) Analysis and Forecast
3.2.1. Historical Market Size Analysis, 2013-2016
3.2.2. Current Market Size Forecast, 2018-2026
3.3. Global Dysmenorrhea Treatment Market Outlook: Diseases
3.3.1. Introduction / Key Findings
3.3.2. Historical Market Size (US$ Mn) and Volume (Units) Analysis By Disease, 2018 - 2022
3.3.3. Current Market Size (US$ Mn) and Volume (Units) Forecast By Disease, 2023 - 2030
3.3.3.1. Primary Dysmenorrhea
3.3.3.2. Secondary Dysmenorrhea
3.3.3.3. Endometriosis
3.3.3.4. Adenomyosis
3.3.3.5. Uterine Myomas
3.3.3.6. Endometrial Polyps
3.3.3.7. Cervical Stenosis
3.3.3.8. Obstructive Malformations of Genital Tract
3.4. Market Attractiveness Analysis: Diseases
3.5. Global Dysmenorrhea Treatment Market Outlook: Therapeutic Class
3.5.1. Introduction / Key Findings
3.5.2. Historical Market Size (US$ Mn) and Volume (Units) Analysis By Therapeutic Class, 2018 - 2022
3.5.3. Current Market Size (US$ Mn) and Volume (Units) Forecast By Therapeutic Class, 2023 - 2030
3.5.3.1. Non-Hormonal Medical Treatment
3.5.3.2. Non-Steroidal Anti-Inflammatory Drugs (NSAIDS)
3.5.3.3. Non-Selective Nsaids
3.5.3.4. Cox-2 Inhibitors
3.5.3.5. Transdermal Glyceryl Trinitrate
3.5.3.6. Over-The-Counter (Otc) Medications
3.5.3.7. Hormonal Medicine Treatment
3.5.3.8. Combined Oral Contraceptive
3.5.3.9. Progestin Regimens
3.5.3.10. Levonorgestrel Intrauterine System (LN-IUS)
3.5.3.11. Surgical Options
3.5.3.12. Laparoscopy
3.5.3.13. Hysterectomy
3.5.3.14. Presacral Neurectomy
3.5.3.15. Laparoscopic Uterosacral Nerve Ablation (LUNA)
3.5.3.16. Intrauterine Device (IUD)
3.6. Market Attractiveness Analysis: Therapeutic Class
4. Global Dysmenorrhea Treatment Market Outlook: Region
4.1. Key Highlights
4.2. Historical Market Size (US$ Mn) and Volume (Units) Analysis By Region, 2018 - 2022
4.3. Current Market Size (US$ Mn) and Volume (Units) Forecast By Region, 2023 - 2030
4.3.1. North America
4.3.2. Europe
4.3.3. East Asia
4.3.4. South Asia and Oceania
4.3.5. Latin America
4.3.6. Middle East & Africa (MEA)
4.4. Market Attractiveness Analysis: Region
5. North America Dysmenorrhea Treatment Market Outlook: Historical (2018 - 2022) and Forecast (2023 - 2030)
5.1. Key Highlights
5.2. Pricing Analysis
5.3. Historical Market Size (US$ Mn) and Volume (Units) Analysis By Market, 2018 - 2022
5.3.1. By Country
5.3.2. By Disease
5.3.3. By Therapeutic Class
5.4. Current Market Size (US$ Mn) and Volume (Units) Forecast By Country, 2023 - 2030
5.4.1. U.S.
5.4.2. Canada
5.5. Current Market Size (US$ Mn) and Volume (Units) Forecast By Disease, 2023 - 2030
5.5.1. Primary Dysmenorrhea
5.5.2. Secondary Dysmenorrhea
5.5.3. Endometriosis
5.5.4. Adenomyosis
5.5.5. Uterine Myomas
5.5.6. Endometrial Polyps
5.5.7. Cervical Stenosis
5.5.8. Obstructive Malformations of Genital Tract
5.6. Current Market Size (US$ Mn) and Volume (Units) Forecast By Therapeutic Class, 2023 - 2030
5.6.1. Non-Hormonal Medical Treatment
5.6.2. Non-Steroidal Anti-Inflammatory Drugs (NSAIDS)
5.6.3. Non-Selective Nsaids
5.6.4. Cox-2 Inhibitors
5.6.5. Transdermal Glyceryl Trinitrate
5.6.6. Over-The-Counter (Otc) Medications
5.6.7. Hormonal Medicine Treatment
5.6.8. Combined Oral Contraceptive
5.6.9. Progestin Regimens
5.6.10. Levonorgestrel Intrauterine System (LN-IUS)
5.6.11. Surgical Options
5.6.12. Laparoscopy
5.6.13. Hysterectomy
5.6.14. Presacral Neurectomy
5.6.15. Laparoscopic Uterosacral Nerve Ablation (LUNA)
5.6.16. Intrauterine Device (IUD)
5.7. Market Attractiveness Analysis
6. Europe Dysmenorrhea Treatment Market Outlook: Historical (2018 - 2022) and Forecast (2023 - 2030)
6.1. Key Highlights
6.2. Pricing Analysis
6.3. Historical Market Size (US$ Mn) and Volume (Units) Analysis By Market, 2018 - 2022
6.3.1. By Country
6.3.2. By Disease
6.3.3. By Therapeutic Class
6.4. Current Market Size (US$ Mn) and Volume (Units) Forecast By Country, 2023 - 2030
6.4.1. Germany
6.4.2. France
6.4.3. U.K.
6.4.4. Italy
6.4.5. Spain
6.4.6. Russia
6.4.7. Türkiye
6.4.8. Rest of Europe
6.5. Current Market Size (US$ Mn) and Volume (Units) Forecast By Disease, 2023 - 2030
6.5.1. Primary Dysmenorrhea
6.5.2. Secondary Dysmenorrhea
6.5.3. Endometriosis
6.5.4. Adenomyosis
6.5.5. Uterine Myomas
6.5.6. Endometrial Polyps
6.5.7. Cervical Stenosis
6.5.8. Obstructive Malformations of Genital Tract
6.6. Current Market Size (US$ Mn) and Volume (Units) Forecast By Therapeutic Class, 2023 - 2030
6.6.1. Non-Hormonal Medical Treatment
6.6.2. Non-Steroidal Anti-Inflammatory Drugs (NSAIDS)
6.6.3. Non-Selective Nsaids
6.6.4. Cox-2 Inhibitors
6.6.5. Transdermal Glyceryl Trinitrate
6.6.6. Over-The-Counter (Otc) Medications
6.6.7. Hormonal Medicine Treatment
6.6.8. Combined Oral Contraceptive
6.6.9. Progestin Regimens
6.6.10. Levonorgestrel Intrauterine System (LN-IUS)
6.6.11. Surgical Options
6.6.12. Laparoscopy
6.6.13. Hysterectomy
6.6.14. Presacral Neurectomy
6.6.15. Laparoscopic Uterosacral Nerve Ablation (LUNA)
6.6.16. Intrauterine Device (IUD)
6.7. Market Attractiveness Analysis
7. East Asia Dysmenorrhea Treatment Market Outlook: Historical (2018 - 2022) and Forecast (2023 - 2030)
7.1. Key Highlights
7.2. Pricing Analysis
7.3. Historical Market Size (US$ Mn) and Volume (Units) Analysis By Market, 2018 - 2022
7.3.1. By Country
7.3.2. By Disease
7.3.3. By Therapeutic Class
7.4. Current Market Size (US$ Mn) and Volume (Units) Forecast By Country, 2023 - 2030
7.4.1. China
7.4.2. Japan
7.4.3. South Korea
7.5. Current Market Size (US$ Mn) and Volume (Units) Forecast By Disease, 2023 - 2030
7.5.1. Primary Dysmenorrhea
7.5.2. Secondary Dysmenorrhea
7.5.3. Endometriosis
7.5.4. Adenomyosis
7.5.5. Uterine Myomas
7.5.6. Endometrial Polyps
7.5.7. Cervical Stenosis
7.5.8. Obstructive Malformations of Genital Tract
7.6. Current Market Size (US$ Mn) and Volume (Units) Forecast By Therapeutic Class, 2023 - 2030
7.6.1. Non-Hormonal Medical Treatment
7.6.2. Non-Steroidal Anti-Inflammatory Drugs (NSAIDS)
7.6.3. Non-Selective Nsaids
7.6.4. Cox-2 Inhibitors
7.6.5. Transdermal Glyceryl Trinitrate
7.6.6. Over-The-Counter (Otc) Medications
7.6.7. Hormonal Medicine Treatment
7.6.8. Combined Oral Contraceptive
7.6.9. Progestin Regimens
7.6.10. Levonorgestrel Intrauterine System (LN-IUS)
7.6.11. Surgical Options
7.6.12. Laparoscopy
7.6.13. Hysterectomy
7.6.14. Presacral Neurectomy
7.6.15. Laparoscopic Uterosacral Nerve Ablation (LUNA)
7.6.16. Intrauterine Device (IUD)
7.7. Market Attractiveness Analysis
8. South Asia & Oceania Dysmenorrhea Treatment Market Outlook: Historical (2018 - 2022) and Forecast (2023 - 2030)
8.1. Key Highlights
8.2. Pricing Analysis
8.3. Historical Market Size (US$ Mn) and Volume (Units) Analysis By Market, 2018 - 2022
8.3.1. By Country
8.3.2. By Disease
8.3.3. By Therapeutic Class
8.4. Current Market Size (US$ Mn) and Volume (Units) Forecast By Country, 2023 - 2030
8.4.1. India
8.4.2. Southeast Asia
8.4.3. ANZ
8.4.4. Rest of South Asia & Oceania
8.5. Current Market Size (US$ Mn) and Volume (Units) Forecast By Disease, 2023 - 2030
8.5.1. Primary Dysmenorrhea
8.5.2. Secondary Dysmenorrhea
8.5.3. Endometriosis
8.5.4. Adenomyosis
8.5.5. Uterine Myomas
8.5.6. Endometrial Polyps
8.5.7. Cervical Stenosis
8.5.8. Obstructive Malformations of Genital Tract
8.6. Current Market Size (US$ Mn) and Volume (Units) Forecast By Therapeutic Class, 2023 - 2030
8.6.1. Non-Hormonal Medical Treatment
8.6.2. Non-Steroidal Anti-Inflammatory Drugs (NSAIDS)
8.6.3. Non-Selective Nsaids
8.6.4. Cox-2 Inhibitors
8.6.5. Transdermal Glyceryl Trinitrate
8.6.6. Over-The-Counter (Otc) Medications
8.6.7. Hormonal Medicine Treatment
8.6.8. Combined Oral Contraceptive
8.6.9. Progestin Regimens
8.6.10. Levonorgestrel Intrauterine System (LN-IUS)
8.6.11. Surgical Options
8.6.12. Laparoscopy
8.6.13. Hysterectomy
8.6.14. Presacral Neurectomy
8.6.15. Laparoscopic Uterosacral Nerve Ablation (LUNA)
8.6.16. Intrauterine Device (IUD)
8.7. Market Attractiveness Analysis
9. Latin America Dysmenorrhea Treatment Market Outlook: Historical (2018 - 2022) and Forecast (2023 - 2030)
9.1. Key Highlights
9.2. Pricing Analysis
9.3. Historical Market Size (US$ Mn) and Volume (Units) Analysis By Market, 2018 - 2022
9.3.1. By Country
9.3.2. By Disease
9.3.3. By Therapeutic Class
9.4. Current Market Size (US$ Mn) and Volume (Units) Forecast By Country, 2023 - 2030
9.4.1. Brazil
9.4.2. Mexico
9.4.3. Rest of Latin America
9.5. Current Market Size (US$ Mn) and Volume (Units) Forecast By Disease, 2023 - 2030
9.5.1. Primary Dysmenorrhea
9.5.2. Secondary Dysmenorrhea
9.5.3. Endometriosis
9.5.4. Adenomyosis
9.5.5. Uterine Myomas
9.5.6. Endometrial Polyps
9.5.7. Cervical Stenosis
9.5.8. Obstructive Malformations of Genital Tract
9.6. Current Market Size (US$ Mn) and Volume (Units) Forecast By Therapeutic Class, 2023 - 2030
9.6.1. Non-Hormonal Medical Treatment
9.6.2. Non-Steroidal Anti-Inflammatory Drugs (NSAIDS)
9.6.3. Non-Selective Nsaids
9.6.4. Cox-2 Inhibitors
9.6.5. Transdermal Glyceryl Trinitrate
9.6.6. Over-The-Counter (Otc) Medications
9.6.7. Hormonal Medicine Treatment
9.6.8. Combined Oral Contraceptive
9.6.9. Progestin Regimens
9.6.10. Levonorgestrel Intrauterine System (LN-IUS)
9.6.11. Surgical Options
9.6.12. Laparoscopy
9.6.13. Hysterectomy
9.6.14. Presacral Neurectomy
9.6.15. Laparoscopic Uterosacral Nerve Ablation (LUNA)
9.6.16. Intrauterine Device (IUD)
9.7. Market Attractiveness Analysis
10. Middle East & Africa Dysmenorrhea Treatment Market Outlook: Historical (2018 - 2022) and Forecast (2023 - 2030)
10.1. Key Highlights
10.2. Pricing Analysis
10.3. Historical Market Size (US$ Mn) and Volume (Units) Analysis By Market, 2018 - 2022
10.3.1. By Country
10.3.2. By Disease
10.3.3. By Therapeutic Class
10.4. Current Market Size (US$ Mn) and Volume (Units) Forecast By Country, 2023 - 2030
10.4.1. GCC
10.4.2. Egypt
10.4.3. South Africa
10.4.4. Northern Africa
10.4.5. Rest of Middle East & Africa
10.5. Current Market Size (US$ Mn) and Volume (Units) Forecast By Disease, 2023 - 2030
10.5.1. Primary Dysmenorrhea
10.5.2. Secondary Dysmenorrhea
10.5.3. Endometriosis
10.5.4. Adenomyosis
10.5.5. Uterine Myomas
10.5.6. Endometrial Polyps
10.5.7. Cervical Stenosis
10.5.8. Obstructive Malformations of Genital Tract
10.6. Current Market Size (US$ Mn) and Volume (Units) Forecast By Therapeutic Class, 2023 - 2030
10.6.1. Non-Hormonal Medical Treatment
10.6.2. Non-Steroidal Anti-Inflammatory Drugs (NSAIDS)
10.6.3. Non-Selective Nsaids
10.6.4. Cox-2 Inhibitors
10.6.5. Transdermal Glyceryl Trinitrate
10.6.6. Over-The-Counter (Otc) Medications
10.6.7. Hormonal Medicine Treatment
10.6.8. Combined Oral Contraceptive
10.6.9. Progestin Regimens
10.6.10. Levonorgestrel Intrauterine System (LN-IUS)
10.6.11. Surgical Options
10.6.12. Laparoscopy
10.6.13. Hysterectomy
10.6.14. Presacral Neurectomy
10.6.15. Laparoscopic Uterosacral Nerve Ablation (LUNA)
10.6.16. Intrauterine Device (IUD)
10.7. Market Attractiveness Analysis
11. Competition Landscape
11.1. Market Share Analysis, 2022
11.2. Market Structure
11.2.1. Competition Intensity Mapping By Market
11.2.2. Competition Dashboard
11.2.3. Apparent Product Capacity
11.3. Company Profiles (Details - Overview, Financials, Strategy, Recent Developments)
11.3.1. Novartis Pharmaceuticals Corporation
11.3.1.1. Overview
11.3.1.2. Segments and Product
11.3.1.3. Key Financials
11.3.1.4. Market Developments
11.3.1.5. Market Strategy
11.3.2. Merck, Inc.
11.3.2.1. Overview
11.3.2.2. Segments and Product
11.3.2.3. Key Financials
11.3.2.4. Market Developments
11.3.2.5. Market Strategy
11.3.3. Bayer Schering Pharma AG
11.3.3.1. Overview
11.3.3.2. Segments and Product
11.3.3.3. Key Financials
11.3.3.4. Market Developments
11.3.3.5. Market Strategy
11.3.4. Vanita Therapeutics
11.3.4.1. Overview
11.3.4.2. Segments and Product
11.3.4.3. Key Financials
11.3.4.4. Market Developments
11.3.4.5. Market Strategy
11.3.5. Alvogen
11.3.5.1. Overview
11.3.5.2. Segments and Product
11.3.5.3. Key Financials
11.3.5.4. Market Developments
11.3.5.5. Market Strategy
11.3.6. Pfizer, Inc.
11.3.6.1. Overview
11.3.6.2. Segments and Product
11.3.6.3. Key Financials
11.3.6.4. Market Developments
11.3.6.5. Market Strategy
11.3.7. Nua
11.3.7.1. Overview
11.3.7.2. Segments and Product
11.3.7.3. Key Financials
11.3.7.4. Market Developments
11.3.7.5. Market Strategy
11.3.8. Cora
11.3.8.1. Overview
11.3.8.2. Segments and Product
11.3.8.3. Key Financials
11.3.8.4. Market Developments
11.3.8.5. Market Strategy
11.3.9. Roche Laboratories
11.3.9.1. Overview
11.3.9.2. Segments and Product
11.3.9.3. Key Financials
11.3.9.4. Market Developments
11.3.9.5. Market Strategy
11.3.10. Taj Pharmaceuticals, Ltd.
11.3.10.1. Overview
11.3.10.2. Segments and Product
11.3.10.3. Key Financials
11.3.10.4. Market Developments
11.3.10.5. Market Strategy
11.3.11. Sanofi
11.3.11.1. Overview
11.3.11.2. Segments and Product
11.3.11.3. Key Financials
11.3.11.4. Market Developments
11.3.11.5. Market Strategy
11.3.12. Terramedic, Inc.
11.3.12.1. Overview
11.3.12.2. Segments and Product
11.3.12.3. Key Financials
11.3.12.4. Market Developments
11.3.12.5. Market Strategy
12. Appendix
12.1. Research Methodology
12.2. Research Assumptions
12.3. Acronyms and Abbreviations
Report Sample is Available
In-depth report coverage is now just a few seconds away
Get FREE Report Sample
Make This Report Your Own
Take Advantage of Intelligence Tailored to your Business Objective
Get a Customized Version
